High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

(2020) Nina Shah et al.   LEUKEMIA

Development of CAR-T cell therapies for multiple myeloma

(2020) Nico Gagelmann et al.   LEUKEMIA

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

(2020) Gils Roex et al.   Journal of Hematology & Oncology

Immune Signatures Associated with Clonal Isotype Switch after Autologous Stem Cell Transplant for Multiple Myeloma

(2019) Rebecca Ye et al.   Clinical Lymphoma Myeloma & Leukemia

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

(2018) David Porter et al.   Journal of Hematology & Oncology

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

(2018) Susanne H. Baumeister et al.   Cancer Immunology Research

Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy

(2017) Jiasheng Wang et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

(2016) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Multiple Myeloma: Diagnosis and Treatment

(2016) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Immunotherapies targeting CD38 in Multiple Myeloma

(2016) Djordje Atanackovic et al.   OncoImmunology

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

(2012) Ivetta Danylesko et al.   Clinical & Developmental Immunology

Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes

(2012) Pilar Brito-Zerón et al.   JOURNAL OF AUTOIMMUNITY

B cells and antibodies in multiple sclerosis pathogenesis and therapy

(2012) Markus Krumbholz et al.   Nature Reviews Neurology

Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance?

(2010) G Sucak et al.   HEMATOLOGICAL ONCOLOGY